Tecovirimat

Tecovirimat
Clinical data
Trade names	Tpoxx
Other names	ST-246
AHFS/Drugs.com	Monograph
License data	US DailyMed: Tecovirimat;
Routes of; administration	By mouth, intravenous
ATC code	J05AX24 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name N-{3,5-Dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl}-4-(trifluoromethyl)benzamide;
CAS Number	869572-92-9;
PubChem CID	16124688;
DrugBank	DB12020;
ChemSpider	17281586 ;
UNII	F925RR824R;
KEGG	D09390 ; as monohydrate: D11557 ;
ChEMBL	ChEMBL1257073 ;
Chemical and physical data
Formula	C19H15F3N2O3
Molar mass	376.335 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)C2C(C3C=CC2C2CC32)C1=O;
	InChI InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25) ; Key:CSKDFZIMJXRJGH-UHFFFAOYSA-N ;

Tecovirimat, sold under the brand name Tpoxx among others, is an antiviral medication with activity against orthopoxviruses such as smallpox and mpox. In 2018 it was the first antipoxviral drug approved in the United States.

The drug works by blocking cellular transmission of orthopoxviruses, thus preventing disease.

Tecovirimat has been effective in laboratory testing; it has been shown to protect animals from mpox and rabbitpox and causes no serious side effects in humans. Tecovirimat was first used for treatment in December 2018, after a laboratory-acquired vaccinia virus infection.

As of 2014 two million doses of tecovirimat were stockpiled in the US Strategic National Stockpile should an orthopoxvirus-based bioterror attack occur. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.